NO20055421D0 - Kinolinderivater som fosfodiestrase-inhibitorer - Google Patents

Kinolinderivater som fosfodiestrase-inhibitorer

Info

Publication number
NO20055421D0
NO20055421D0 NO20055421A NO20055421A NO20055421D0 NO 20055421 D0 NO20055421 D0 NO 20055421D0 NO 20055421 A NO20055421 A NO 20055421A NO 20055421 A NO20055421 A NO 20055421A NO 20055421 D0 NO20055421 D0 NO 20055421D0
Authority
NO
Norway
Prior art keywords
phosphodiesterase inhibitors
quinoline derivatives
quinoline
derivatives
phosphodiesterase
Prior art date
Application number
NO20055421A
Other languages
English (en)
Other versions
NO20055421L (no
NO330754B1 (no
Inventor
Brian Evans
Stephen Barry Guntrip
Michael David Barker
Alison Judith Redgrave
Stuart Holman
Paul Spencer Jones
Ian Robert Baldwin
Colin David Eldred
Christopher James Lunniss
Julie Nicole Hamblin
Mika Kristian Lindvall
Anthony William Dean
Sharon Lisa Gough
Tracy Jane Redfern
John Edward Robinson
Michael Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311688A external-priority patent/GB0311688D0/en
Priority claimed from GB0326187A external-priority patent/GB0326187D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20055421D0 publication Critical patent/NO20055421D0/no
Publication of NO20055421L publication Critical patent/NO20055421L/no
Publication of NO330754B1 publication Critical patent/NO330754B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
NO20055421A 2003-05-21 2005-11-16 Kinolinderivater, fremgangsmate for fremstilling av slike, farmasoytiske formuleringer omfattende slike, slike forbindelser i medisinsk terapi samt slike forbindelser for behandling av sykdom NO330754B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0311688A GB0311688D0 (en) 2003-05-21 2003-05-21 Compounds
GB0326187A GB0326187D0 (en) 2003-11-10 2003-11-10 Compounds
PCT/EP2004/005494 WO2004103998A1 (en) 2003-05-21 2004-05-19 Quinoline derivatives as phosphodiesterase inhibitors

Publications (3)

Publication Number Publication Date
NO20055421D0 true NO20055421D0 (no) 2005-11-16
NO20055421L NO20055421L (no) 2005-12-20
NO330754B1 NO330754B1 (no) 2011-07-04

Family

ID=33477765

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055421A NO330754B1 (no) 2003-05-21 2005-11-16 Kinolinderivater, fremgangsmate for fremstilling av slike, farmasoytiske formuleringer omfattende slike, slike forbindelser i medisinsk terapi samt slike forbindelser for behandling av sykdom

Country Status (31)

Country Link
US (4) US7566786B2 (no)
EP (2) EP1633748B1 (no)
JP (1) JP4625460B2 (no)
KR (1) KR101144548B1 (no)
CN (1) CN1823063B (no)
AR (1) AR044401A1 (no)
AT (2) ATE388148T1 (no)
AU (1) AU2004240759B2 (no)
BR (1) BRPI0410477A (no)
CA (1) CA2526228C (no)
CO (1) CO5700780A2 (no)
CY (2) CY1108094T1 (no)
DE (1) DE602004012260T2 (no)
DK (2) DK1633748T3 (no)
EG (1) EG24774A (no)
ES (2) ES2374850T3 (no)
HK (2) HK1092458A1 (no)
HR (2) HRP20080236T3 (no)
IL (1) IL171726A (no)
IS (1) IS2581B (no)
MA (1) MA27808A1 (no)
MX (1) MXPA05012466A (no)
NO (1) NO330754B1 (no)
NZ (1) NZ543554A (no)
PL (2) PL1633748T3 (no)
PT (2) PT1944305E (no)
RU (1) RU2335493C2 (no)
SI (2) SI1633748T1 (no)
TW (1) TWI328009B (no)
WO (1) WO2004103998A1 (no)
ZA (1) ZA200509319B (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0425572D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0503955D0 (en) * 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
GB0505621D0 (en) * 2005-03-18 2005-04-27 Glaxo Group Ltd Novel compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
MX2008011257A (es) * 2006-03-08 2008-09-25 Amgen Inc Derivados de quinolina e isoquinolina como inhibidores de fosfodiesterasa 10.
GB0605462D0 (en) * 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
MX2008013511A (es) * 2006-04-28 2008-10-28 Shionogi & Co Derivados de amina que tienen actividad antagonista del receptor neuropeptido y y5.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PE20080943A1 (es) 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
KR20160129109A (ko) 2008-05-23 2016-11-08 아미라 파마슈티칼스 인코포레이티드 5-리폭시게나아제 활성화 단백질 억제제
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
EP2379076B1 (en) * 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2010097248A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN102439151A (zh) 2009-03-19 2012-05-02 默沙东公司 使用短干扰核酸（siNA）的RNA干扰介导的BTB和CNC同系物1，碱性亮氨酸拉链转录因子1（Bach1）基因表达的抑制
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004282A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp, RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521762A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20100273744A1 (en) 2009-04-24 2010-10-28 Paul Martin Gore Compounds
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
EA021056B1 (ru) 2009-04-30 2015-03-31 Глаксо Груп Лимитед Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ, содержащая их фармацевтическая композиция и их применение в лечении расстройств, опосредованных ненадлежащей активностью pi3-киназ
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
JP2014504269A (ja) * 2010-11-05 2014-02-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 化学化合物
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
CA2829131C (en) * 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
MX344308B (es) * 2011-11-03 2016-12-13 Merck Sharp & Dohme Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN104968200B (zh) 2013-02-01 2018-03-06 维尔斯达医疗公司 具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
KR20150118152A (ko) 2013-02-21 2015-10-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 퀴나졸린
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CN107072976A (zh) 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
US10100015B2 (en) * 2015-03-24 2018-10-16 Shanghai Yingli Pharmaceutical Co., Ltd. Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
MX2019007276A (es) * 2016-12-22 2019-11-11 Mavupharma Inc Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE46886B1 (en) 1977-05-17 1983-10-19 Allen & Hanburys Ltd Aminoalkyl-benzene derivatives
EP0048005A3 (de) * 1980-09-17 1983-01-19 ALFA-Institut für hauswirtschaftliche Produkt- und Verfahrens-Entwicklung GmbH Vorrichtung zum Stapeln von Geschirr
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
EP0480052B1 (en) 1990-03-28 1998-01-14 Otsuka Pharmaceutical Co., Ltd. Quinoline derivative, antiulcer drug containing the same, and production of said derivative
US5214191A (en) 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
DE69435280D1 (de) 1993-03-10 2010-04-15 Glaxosmithkline Llc Phosphodiesterase des menschlichen Gehirns und Screening-Verfahren
FR2705346B1 (fr) 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
USRE39576E1 (en) 1994-06-15 2007-04-17 Smithkline Beecham Corporation Enzyme inhibitors
AU722662B2 (en) * 1996-05-20 2000-08-10 Darwin Discovery Limited Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors
AU3766897A (en) 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
PL341364A1 (en) 1997-12-22 2001-04-09 Upjohn Co 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
BRPI9914164B8 (pt) 1998-09-29 2021-05-25 American Cyanamid Co compostos de 3-ciano quinolina
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
AR028986A1 (es) 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
BR0008731A (pt) 1999-03-15 2002-09-24 Abbott Lab Macrolìdeos 6-0-substituìdos, tendo atividade antibacteriana
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AU2001289749B9 (en) 2000-07-26 2004-08-19 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
CA2423251A1 (en) 2000-09-29 2002-04-04 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
WO2002036570A1 (en) 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
MXPA04003758A (es) 2001-10-22 2005-06-20 Univ New York State Res Found Inhibidores de proteina - cinasas y proteina-fosfatasas, metodos para disenarlos y metodos para usarlos.
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOQUINOLINE COMPOUNDS
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
NZ552283A (en) 2002-06-20 2008-07-31 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
JP2006519846A (ja) 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
KR101144548B1 (ko) 2012-05-11
EP1633748A1 (en) 2006-03-15
US20060178416A1 (en) 2006-08-10
ZA200509319B (en) 2007-02-28
HK1092458A1 (en) 2007-02-09
ES2301993T3 (es) 2008-07-01
IS2581B (is) 2010-02-15
PL1944305T3 (pl) 2012-03-30
NO20055421L (no) 2005-12-20
AR044401A1 (es) 2005-09-14
DE602004012260T2 (de) 2009-03-12
SI1944305T1 (sl) 2012-02-29
TWI328009B (en) 2010-08-01
HRP20080236T3 (en) 2008-06-30
DK1633748T3 (da) 2008-06-30
KR20060015278A (ko) 2006-02-16
CY1112232T1 (el) 2015-12-09
RU2335493C2 (ru) 2008-10-10
TW200500358A (en) 2005-01-01
IL171726A (en) 2013-07-31
ATE529421T1 (de) 2011-11-15
SI1633748T1 (sl) 2008-08-31
PT1944305E (pt) 2012-01-11
US20070142373A1 (en) 2007-06-21
ES2374850T3 (es) 2012-02-22
BRPI0410477A (pt) 2006-05-30
AU2004240759A1 (en) 2004-12-02
US20090312325A1 (en) 2009-12-17
EP1944305A1 (en) 2008-07-16
HK1118274A1 (en) 2009-02-06
RU2005135016A (ru) 2006-06-27
HRP20110957T1 (hr) 2012-01-31
US7572915B2 (en) 2009-08-11
CA2526228C (en) 2010-08-03
US7566786B2 (en) 2009-07-28
AU2004240759B2 (en) 2010-03-04
US20070049570A1 (en) 2007-03-01
MXPA05012466A (es) 2006-01-30
EP1633748B1 (en) 2008-03-05
DE602004012260D1 (no) 2008-04-17
CN1823063A (zh) 2006-08-23
CY1108094T1 (el) 2014-02-12
PT1633748E (pt) 2008-05-20
NO330754B1 (no) 2011-07-04
WO2004103998A1 (en) 2004-12-02
CN1823063B (zh) 2010-07-14
IS8110A (is) 2005-10-31
DK1944305T3 (da) 2012-01-30
JP2007501264A (ja) 2007-01-25
EP1944305B1 (en) 2011-10-19
CO5700780A2 (es) 2006-11-30
JP4625460B2 (ja) 2011-02-02
EG24774A (en) 2010-08-19
MA27808A1 (fr) 2006-03-01
CA2526228A1 (en) 2004-12-02
NZ543554A (en) 2008-09-26
PL1633748T3 (pl) 2008-07-31
ATE388148T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
DK1944305T3 (da) Quinolinderivater som phosphodiesteraseinhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
IS8439A (is) Nýjar kínólín afleiður
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2301544T3 (da) Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
ATE481402T1 (de) Pyrazolopyridin-derivate
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DE60336732D1 (de) Azaindol-kinaseinhibitoren
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
ATE529428T1 (de) Thioxanthinderivate als myeloperoxidaseinhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1633712T3 (da) Seks leddede amino-amid derivater som angiogenese inhibitorer
IS8242A (is) Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar
DE602004011548D1 (de) 4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

MM1K Lapsed by not paying the annual fees